Associations between polyunsaturated fatty acid concentrations and Parkinson's disease: A two-sample Mendelian...

Area of Science:

• Nutritional Neuroscience
• Genetic Epidemiology
• Neurodegenerative Diseases

Background:

• Observational studies show conflicting results on the effect of polyunsaturated fatty acids (PUFAs) on Parkinson's disease (PD).
• Existing randomized controlled trials suggest potential PD symptom improvement with PUFA supplementation but are limited by small sample sizes and short intervention durations.

Purpose of the Study:

• To investigate the causal relationship between genetically predicted plasma levels of various PUFAs and the risk of developing Parkinson's disease (PD).
• To differentiate direct causal effects from pleiotropic effects using advanced Mendelian randomization techniques.

Main Methods:

• Employed a two-sample Mendelian randomization design utilizing genetic variants for PUFAs as instrumental variables.
• Leveraged large-scale genome-wide association study data for Parkinson's disease (33,674 cases, 449,056 controls).
• Applied inverse variance weighted (IVW) and multivariable Mendelian randomization (MVMR) methods, alongside sensitivity analyses to ensure robustness and address potential pleiotropy and weak instrument bias.

Main Results:

• Elevated plasma levels of arachidonic acid (AA) were associated with a statistically significant increase in PD risk (OR=1.03 per 1-SD increase, P=2.24E-04).
• Increased eicosapentaenoic acid (EPA) levels showed a potential association with higher PD risk after adjusting for pleiotropy (MVMR; OR=1.05, P=5.40E-03).
• No causal associations were found between PD risk and linoleic acid (LA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), or alpha-linolenic acid (ALA).

Conclusions:

• Mendelian randomization analysis suggests that higher circulating levels of AA and potentially EPA may be associated with an increased risk of Parkinson's disease.
• The study found no evidence of a causal link between other common PUFAs (LA, DHA, DPA, ALA) and PD risk.
• Findings warrant cautious interpretation in clinical practice, emphasizing the need for further research into the complex relationship between PUFAs and PD.